Sovereign Investment Advisors LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,111 shares of the company’s stock, valued at approximately $309,000.
A number of other large investors have also modified their holdings of the business. State Street Corp grew its holdings in shares of Merck & Co., Inc. by 1.3% in the third quarter. State Street Corp now owns 119,026,412 shares of the company’s stock valued at $13,606,360,000 after purchasing an additional 1,536,474 shares during the period. Wellington Management Group LLP grew its holdings in shares of Merck & Co., Inc. by 4.6% in the third quarter. Wellington Management Group LLP now owns 75,809,383 shares of the company’s stock valued at $8,608,914,000 after purchasing an additional 3,327,404 shares during the period. Geode Capital Management LLC grew its holdings in shares of Merck & Co., Inc. by 3.7% in the third quarter. Geode Capital Management LLC now owns 59,155,004 shares of the company’s stock valued at $6,696,060,000 after purchasing an additional 2,134,296 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Merck & Co., Inc. by 29.7% in the fourth quarter. Bank of New York Mellon Corp now owns 24,213,537 shares of the company’s stock valued at $2,408,763,000 after purchasing an additional 5,550,824 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Merck & Co., Inc. by 7.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 20,125,171 shares of the company’s stock valued at $2,002,052,000 after purchasing an additional 1,317,878 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on MRK shares. TD Securities lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price objective for the company from $121.00 to $100.00 in a report on Monday, February 10th. Leerink Partners lowered their target price on shares of Merck & Co., Inc. from $136.00 to $119.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. Truist Financial reaffirmed a “hold” rating and set a $110.00 target price (down previously from $130.00) on shares of Merck & Co., Inc. in a research note on Wednesday, January 8th. Morgan Stanley lowered their target price on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. Finally, BMO Capital Markets lowered their target price on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a “market perform” rating for the company in a research note on Wednesday, February 5th. Eleven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $117.12.
Insider Activity at Merck & Co., Inc.
In other Merck & Co., Inc. news, insider Cristal N. Downing sold 2,361 shares of the stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $88.76, for a total value of $209,562.36. Following the transaction, the insider now directly owns 7,085 shares in the company, valued at $628,864.60. This represents a 24.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Inge G. Thulin purchased 2,833 shares of the company’s stock in a transaction on Thursday, February 6th. The stock was bought at an average price of $88.25 per share, for a total transaction of $250,012.25. Following the completion of the purchase, the director now directly owns 2,933 shares of the company’s stock, valued at $258,837.25. The trade was a 2,833.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.09% of the stock is owned by corporate insiders.
Merck & Co., Inc. Stock Up 0.0 %
Shares of NYSE:MRK opened at $94.72 on Friday. The firm’s 50 day moving average price is $93.57 and its 200 day moving average price is $101.88. The stock has a market cap of $239.27 billion, a price-to-earnings ratio of 14.07, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. Merck & Co., Inc. has a fifty-two week low of $81.04 and a fifty-two week high of $134.63. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its earnings results on Tuesday, February 4th. The company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.85 by ($0.13). The firm had revenue of $15.62 billion during the quarter, compared to analyst estimates of $15.51 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The firm’s revenue was up 6.8% compared to the same quarter last year. During the same period last year, the business earned $0.03 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.
Merck & Co., Inc. Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be issued a $0.81 dividend. The ex-dividend date is Monday, March 17th. This represents a $3.24 annualized dividend and a yield of 3.42%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 48.14%.
Merck & Co., Inc. declared that its Board of Directors has approved a stock buyback plan on Tuesday, January 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 4.1% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.
About Merck & Co., Inc.
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Recommended Stories
- Five stocks we like better than Merck & Co., Inc.
- How to Invest in Insurance Companies: A Guide
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is the Australian Securities Exchange (ASX)
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What Are Dividend Contenders? Investing in Dividend Contenders
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.